Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Standards of Care II01:19

Standards of Care II

736
Nurses bear specific legal responsibilities under several federal statutes, including:
736
Continuing Care01:25

Continuing Care

1.6K
Continuing care describes the variety of health, personal, and social services provided over a prolonged period. The need for continuing care is increasing because people are living longer. Many people do not have families or others to care for them. Continuing care is mainly for patients who are disabled, functionally dependent, or suffering from a terminal disease. It is available within institutional settings or in homes. Examples include nursing centers or facilities, assisted living,...
1.6K
Standards of Care I01:22

Standards of Care I

775
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
775
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

234
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
234
Tumor Progression02:07

Tumor Progression

6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same author

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026.

Mayo Clinic proceedings·2026
Same author

Genetic risk and immune dysregulation of classic Hodgkin lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma: a multicentric study.

medRxiv : the preprint server for health sciences·2026
Same author

Proteomic and phosphoproteomic signatures of disease progression in unmutated IGHV chronic lymphocytic leukemia.

Clinical proteomics·2026
Same author

Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.

Leukemia·2026
Same author

Next-generation sequencing for lymphoid neoplasms: Real-world utility from a clinical assay.

Human pathology·2026
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Related Experiment Video

Updated: Oct 3, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.9K

CLL update 2022: A continuing evolution in care.

Neil E Kay1, Paul J Hampel1, Daniel L Van Dyke2

  • 1Division of Hematology, Mayo Clinic, Rochester, MN, United States of America.

Blood Reviews
|February 13, 2022
PubMed
Summary
This summary is machine-generated.

Novel agents like BTK and BCL2 inhibitors are preferred for chronic lymphocytic leukemia (CLL). Time-limited combinations show promise for high-risk patients, but challenges like intolerance and relapse require further research.

Keywords:
CLLDiagnosisFrontline therapiesPrognosisRelapsed therapies

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.6K
Learning Modern Laryngeal Surgery in a Dissection Laboratory
07:30

Learning Modern Laryngeal Surgery in a Dissection Laboratory

Published on: March 18, 2020

8.3K

Related Experiment Videos

Last Updated: Oct 3, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.9K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.6K
Learning Modern Laryngeal Surgery in a Dissection Laboratory
07:30

Learning Modern Laryngeal Surgery in a Dissection Laboratory

Published on: March 18, 2020

8.3K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chronic lymphocytic leukemia (CLL) diagnosis relies on specific B-cell immunophenotypes.
  • Prognostic models like CLL-International Prognostic Index (CLL-IPI) aid in patient risk assessment.
  • High-risk CLL is defined by del17p13, TP53 mutations, and complex karyotype.

Purpose of the Study:

  • To review current therapeutic strategies for CLL, focusing on novel agents.
  • To discuss the efficacy of time-limited doublet and triplet therapies.
  • To identify unmet needs and future research directions in CLL treatment.

Main Methods:

  • Review of phase 3 clinical trials and current research on novel agents for CLL.
  • Analysis of data comparing novel agents with chemoimmunotherapy.
  • Examination of studies investigating combinations and time-limited treatment approaches.

Main Results:

  • Novel agents, including Bruton tyrosine kinase inhibitors (BTKi) and BCL2 inhibitors, are preferred over chemoimmunotherapy for CLL.
  • Time-limited doublet and triplet therapies achieve high response rates and undetectable minimal residual disease (uMRD).
  • Intolerance and disease progression, particularly in high-risk CLL, remain significant challenges.

Conclusions:

  • Continuous therapy with novel agents is the current standard, with time-limited approaches showing promise.
  • Further research is needed to address intolerance, predict relapse, define optimal time-limited strategies, and explore cellular therapies for residual disease in CLL.